Stock Analiz

TriSalus Life Sciences, Inc. TLSI

Medical Specialities · IPO 2021 · data as of November 13, 2026

$2.43Market cap $150M
Open the interactive analysis →

TriSalus Life Sciences, Inc. (TLSI) is a healthcare company listed in the US with a market value of about $150M. In the twelve months to September 30, 2026 it had revenue of $46M and net income of -$26M, a net margin of -56.6%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -4266%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 91% below the current price.

About TriSalus Life Sciences

TriSalus Life Sciences is listed in the US and classified in medical specialities, IPO year 2021. Revenue went from $12M in 2022 to $45M in 2025, growth of about 53.9% a year. It was profitable in 1 of the last 5 years in our data. Its share count rose by 12141% over three years (dilution for shareholders). It spends 33% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S3.2
P/B220.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-16.5%
Shareholder yield0.0%
Intrinsic value vs. price−91%

Growth and quality

Revenue growth (1 yr)53.4%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-222.6%
ROIC (5-yr avg.)-4266.0%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 5 years

Fiscal yearTTM20252024202320222021
Revenue$46M$45M$29M$19M$12M—
Net income-$26M-$39M-$30M-$59M-$47M$5M
Free cash flow-$25M-$19M-$41M-$51M-$33M—
EPS (diluted)$-0.40$-1.84$-1.31$-6.77$-161.55—
Net margin-56.6%-86.9%-102.1%-320.7%-380.6%—
ROIC—-4266.0%————

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is TriSalus Life Sciences stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 91% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does TriSalus Life Sciences pay a dividend?

Not currently.

Is TriSalus Life Sciences a good stock to buy?

We do not give buy or sell advice. TriSalus Life Sciences scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.